Haruki Uojima
A5084731951- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Liver Disease and Transplantation
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis B Virus Studies
- Gallbladder and Bile Duct Disorders
- HIV/AIDS drug development and treatment
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Systemic Lupus Erythematosus Research
- Organ Transplantation Techniques and Outcomes
- Pancreatitis Pathology and Treatment
- Platelet Disorders and Treatments
- Abdominal vascular conditions and treatments
- Cancer, Hypoxia, and Metabolism
- Liver Diseases and Immunity
- Endoplasmic Reticulum Stress and Disease
- Chronic Lymphocytic Leukemia Research
- Pediatric Hepatobiliary Diseases and Treatments
- Nutrition and Health in Aging
- Cancer Mechanisms and Therapy
- MRI in cancer diagnosis
- Cancer Immunotherapy and Biomarkers
- Electrolyte and hormonal disorders
- Optimism, Hope, and Well-being
Kitasato University
2016-2025
National Center for Global Health and Medicine
2023-2025
Shonan Kamakura General Hospital
2015-2024
Kitasato University Hospital
2021-2024
National Institute for Japanese Language and Linguistics
2024
Second Affiliated Hospital of Xi'an Jiaotong University
2024
Kaohsiung Medical University
2024
National Sun Yat-sen University
2024
Weatherford College
2023
GTx (United States)
2017-2023
HCC risk in chronic hepatitis B (CHB) is higher the indeterminate phase compared with inactive phase. However, it unclear if antiviral therapy reduces this population. We aimed to evaluate association between and
There are limited data on antiviral treatment
Background: Low skeletal muscle mass is significantly associated with severe adverse events (AEs) from chemotherapy, and low tolerability leads to decreased survival. We aimed investigate whether body correlated prognosis in patients hepatocellular carcinoma (HCC) treated lenvatinib. Methods: This multicenter, retrospective study was conducted at five locations Japan. included 100 HCC Skeletal measured by computed tomography normalized for height m2 as index (SMI). The assessment criteria...
The aim of this retrospective multicenter study was to clarify the antifibrotic effect and long-term outcome sodium glucose cotransporter 2 inhibitors (SGLT2-Is) in patients with nonalcoholic fatty liver disease (NAFLD) complicated by type diabetes mellitus (T2DM). Of 1262 consecutive T2DM who recently received SGLT2-Is, 202 NAFLD had been receiving SGLT2-Is for more than 48 weeks were subjected analysis. Furthermore, 109 on SGLT2-I therapy 3 years at time analysis assessed effects SGLT2-Is....
Summary Background Racial and ethnic disparities exist for hepatitis C virus (HCV) treatment hepatocellular carcinoma (HCC) survival. Aim To evaluate the impact of HCV on such disparities. Methods In a retrospective cohort study, we analysed 6069 patients with HCV‐related HCC (54.2% Asian, 30.1% White, 8.5% Black, 7.3% Hispanic) from centres in United States Asia. Results The mean age was 61, 60, 59 68, respectively, Hispanic Asian patients. Black were most likely to have Barcelona Clinic...
Pancreatic cancer (PC) is a challenging malignancy to treat. Mac-2-binding protein glycan isomer (M2BPGi) novel serum marker of liver fibrosis and hepatocellular carcinoma secreted by hepatic stellate stroma cells. Serum M2BPGi levels are upregulated in PC patients. We measured the expression 27 patients determined whether affects malignant potential cells vitro. also examined effect M2BP on tumor growth gemcitabine sensitivity vivo. were higher compared with those healthy subjects....
To assess the safety, efficacy and prognostic impact of clinical factors related to lenvatinib treatment in Child-Pugh class A (CP-A) B (CP-B) patients with unresectable hepatocellular carcinoma (u-HCC).Patients u-HCC who were treated at multiple centers Japan retrospectively analyzed for outcomes according their respective CP status. Radiological objective response (OR) was assessed using modified evaluation criteria solid tumors (mRECIST) guidelines.Baseline demographic parameters...
Patients with chronic hepatitis C are often complicated by kidney disease (CKD).To evaluate the efficacy, safety and pharmacokinetics of glecaprevir/pibrentasvir in patients severe renal impairment.In a prospective, multicentre study involving 35 medical institutions, 832 genotype 1-3 were treated glecaprevir/pibrentasvir. The efficacy analysed for CKD stage 4 or 5. Multivariate analysis was performed to identify factors associated most frequently observed adverse event. In undergoing...
Predictive biomarkers of the response hepatocellular carcinoma (HCC) to Lenvatinib therapy have not yet been clarified. The aim this study was identify clinically significant therapy, target strategies against HCC. Levels circulating angiogenic factors (CAFs) were analyzed in blood samples collected at baseline and after introducing lenvatinib, from 74 Child-Pugh class A HCC patients who received lenvatinib. As CAF biomarkers, serum vascular endothelial growth factor (VEGF), fibroblast 19...
Background and Aims Real‐world data for treatment effectiveness renal outcomes in chronic hepatitis B (CHB) patients who were switched to the new safer prodrug tenofovir alafenamide (TAF) from disoproxil fumarate (TDF) are limited. Therefore, we aimed evaluate of this population. Approach Results We analyzed 834 with CHB previously treated TDF ≥12 months TAF routine practice at 13 US Asian centers changes viral (HBV DNA < 20 IU/mL), biochemical (alanine aminotransferase [ALT] 35/25 U/L...
To assess the impact of clinical factors on safety and efficacy atezolizumab plus bevacizumab (ATZ + BV) treatment in patients with unresectable hepatocellular carcinoma (u-HCC).Ninety-four u-HCC who were treated ATZ BV at multiple centers enrolled. We defined Child-Pugh (CP)-A received as a first line therapy 'meets broad sense IMbrave150 criteria' group (B-IMbrave150-in, n = 46), later or CP-B (regardless whether was therapy) B-IMbrave150-out (n 48). Patients retrospectively analyzed for...
The aim of this study was to assess the effect branched-chain amino acid (BCAA) supplements on muscle strength and mass in patients with liver cirrhosis.We carried out a single-center, prospective adult cirrhotic receiving nutrition therapy at Shonan Kamakura General Hospital. A 28-day pretreatment observation period followed by 24-week treatment period. Patients who fulfilled criteria received one package oral BCAA supplement powder twice day response evaluated. responder defined as patient...
The Streptococcus salivarius (S. salivarius) group, which produces the enzyme urease has been identified as a potential contributor to ammonia production in gut. Researchers have reported that patients with minimal HE had an increased abundance of S. is specific change gut microbiota distinguishes them from healthy individuals. correlation between aggregation bacterial species and fibrosis progression chronic liver disease (CLD) yet be fully elucidated. To quantify using digital PCR (dPCR)...
Aims To assess the safety, efficacy, and prognostic impact of clinical factors associated with lenvatinib treatment in highly advanced hepatocellular carcinoma (HCC) tumor thrombus main portal vein trunk (VP4) or more than 50% liver occupation (tm50%LO). Methods A total 61 HCC patients (41 tm50%LO 20 VP4) who were treated at multicenter enrolled retrospectively analyzed for outcomes according to their status, including morphology. Results The most frequent grade ≥3 adverse event was elevated...
BACKGROUND Esophageal variceal bleeding is a severe complication associated with liver cirrhosis and typically necessitates endoscopic hemostasis. The current standard treatment ligation (EVL), Western guidelines recommend antibiotic prophylaxis following However, given the improvements in prognosis for due to advancements management of treatments global concerns regarding emergence multidrug-resistant bacteria, there need reassess use routine after AIM To evaluate effectiveness patients...
Abstract Background and study aims Although the number of resistant bacteria tends to increase with prolonged antimicrobial therapy, no studies have examined relationship between duration therapy in acute cholangitis. We hypothesized that short-term administration agents cholangitis would suppress bacterial resistance. Patients methods This was a single-center, retrospective, observational patients admitted January 2018 June 2020 who met following criteria: successful biliary drainage,...
Abstract Background and Aim This study aimed to evaluate the efficacy safety of elbasvir/grazoprevir in genotype 1b chronic hepatitis C Japanese patients with kidney disease (CKD), including those undergoing hemodialysis. Methods post hoc analysis a multicenter, retrospective included who had received elbasvir/grazoprevir. CKD was defined by an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m 2 . The sustained virologic response (SVR) frequency treatment‐emergent adverse...
Abstract Background In clinical trials, a pangenotype direct‐acting antiviral (DAA) regimen consisting of glecaprevir (GLE) and pibrentasvir (PIB) exhibited high virologic efficacy tolerability in patients with hepatitis C virus (HCV) infection. This study sought to confirm these findings real‐world settings, focusing on cirrhosis, history DAA failure, or HCV genotype 3 who were treated 12‐week large multicenter from Japan. Methods nationwide prospective cohort study, we analyzed background...